Invest in Us

Despite the safety and efficacy of OSCN-, it has never been commercialised.  There are reasons for this.  So, the task I set myself was to overcome the perceived weaknesses and develop formulations and techniques to make OSCN- available to the world.  Now that I have achieved my objectives, I am ready to launch the technology to the world.

We seek investors and funds into UNEEKE TECHNOLOGIES LTD.  UNEEKE will take on the responsibility to strengthen the knowledge and competence of and about HYPOTHIOCYANITE.  

UNEEKE TECHNOLOGIES LTD will acquire Technology and IP relating to HYPOTHIOCYANITE from Qures Group Ltd. The first step, now that we have identified suitable raw materials, is to have clinical work to verify the safety of the molecule and then human clinical trials against one or more conditions.  

Whilst numerous academic papers have shown this already, we anticipate that regulators will be looking for evidence created using more modern techniques and standards. Some of this work is already contracted and underway and the first of several animal and human clinical trials will happen very soon, after the Safety status is confirmed.

All the technology and IP will be owned by UNEEKE TECHNOLOGIES LTD and will earn income from selling licences (big and small) around the world followed by royalties, also big and small, from the successes of the Licensees. Licensees to come from interested, competent and capable parties involved both geographically, commercially and experienced in the application of the technology. The extent of direct marketing and sales will be reviewed by independent consultants to determine, assess and compare the relative values of each possible method so as to help us identify how we proceed.

We see enormous benefits for users of the QURES/UNEEKE Technology. 

Examples, for the health industry and users, are:

1. Overcome Antibiotic Resistance (ABR and AMR).
2. Reduce time in hospital for recovery from infections.
3. Faster delivery of an effective treatment without having to wait for diagnosis.
4. Shorten the period away from work for employees on the 3-4 occasions each year that URTI infections leave them unable to work.
5. Eventually have the products regulated and allowed for OTC availability.

These attributes and cost savings will be of enormous interest to Hospitals, Insurance companies and Governments, plus employers will be able to reduce lost working days by their employees.

For Medicine the licence will be retained within UNEEKE, under a new subsidiary company named UBIQ MEDICINES Ltd, into which we will take separate investors, and this we expect will become the largest Licensee of the QURES/UNEEKE technology. Because the technology and availability of HYPOTHIOCYANITE is NEW, it is our intention to establish THE UNEEKE ACADEMY to ensure full and correct knowledge and understanding is available to our Licensees and their clients.

Our Teachers and Trainers will travel as necessary and residential courses will also be available.  The Academy, with the close involvement with UBIQ,  will allow UNEEKE to monitor, protect and maintain our leadership of HYPOTHIOCYANITE IP.If you want to become financially involved with this exciting venture into the future of human and planet health worldwide, please, complete and submit the INTEREST FORM below. The more information you can provide, that explains who you are and why an investment in UNEEKE is of interest, the better able we are to respond specifically to you. 

You can expect a prompt reply, following our acknowledgement of your interest.  You will be granted access to our Investor site so you can keep abreast of what we are planning, doing and achieving.

You will be asked to complete CDA that ensure you restrict using any confidential details, that we share with you, exclusively to evaluate your investment in UNEEKE TECHNOLOGIES LTD.